REMARKS

Applicants respectfully request entry of the present amendments.

Amendments to the Specification

The Sequence Listing has been amended to modify the description of SEQ ID NOS: 1-4, 25, and 29-32; and to add the CDR sequences shown in Figure 17 (SEQ ID NOS: 33-38).

Figure 17 has been amended to add sequence identification numbers for the CDR sequences (SEQ ID NOS: 33-38). Applicants provide herewith Replacement Sheets for Figure 17.

No new material is added by the present amendments to the specification.

Amendments to the Claims

Prior to the present amendment, claims 34-57 were pending. Claims 46 and 48-57 were previously withdrawn due to restriction requirement, which has been made final. With this reply, new claims 58-65 have been added, and claims 41 and 43-45 have been amended.

Claim 41 has been amended to correct antecedent basis.

Claims 43-45 have been amended to correct minor typographical errors.

New claim 58 combines the features of previously pending claims 44 and 45, and further specifies the feature of claim 34, namely, "the glycosylation of its variable region has been modified," by referring to the glycosylation site Asn47 to Thr49 in the immunoglobulin heavy chain. Support for the feature "wherein the glycosylation site at positions Asn47 to Thr49 of SEQ ID NO: 2 is mutated," referring to mutations at one or more of positions 47, 48, and/or 49, can be found in the specification, for example, at page 9, lines 11-15:

> In a particular embodiment of the present invention, said antibody is the recombinant antibody of Krix-1 or a fragment thereof, produced in any suitable host cell, e.g. in CHO cells. In a yet more particular embodiment, said antibody is a mutant of Krix-1 with modified N-glysosylation in the variable region, **more particularly with a mutated glycosylation site at positions Asn47 to Thr49,** more in particular with Asn47 changed to Gln47 (KRIX-1Q), Glu47 (KRIX-1E) or Asp47 (KRIX-1D) and/or Thr49 to Ala49 (KRIX-1A). (Emphasis added)

Support for this amendment is also found at page 12, lines 5-7 of the specification:

> More particularly the pharmaceutical compound comprises one or more monoclonal antibodies which have been modified in the glycosylation in the region Asn47-Thr49.

New claims 59 and 60 refer to specific mutations in the glycosylation site at positions Asn47 to Thr49 of SEQ ID NO: 2. Support for this amendment is also found in the specification, for example, in the above-cited passages.

New claim 61 combines the features of previously pending claims 42 and 43, and further specifies the feature of claim 34, namely, "the glycosylation of its variable region has been modified," by referring to the glycosylation site Asn47 to Thr49 in the immunoglobulin heavy chain. Support for this amendment is found in the specification, for example, at page 9, lines 11-15, and page 12, lines 5-7.

New claims 62 and 63 specify particular mutations in this glycosylation site at positions Asn 47 to Gln47 of SEQ ID NO: 1. Support for this amendment is also found in the specification at page 9, lines 11-15, and page 12, lines 5-7.

New claim 64 defines the antibody with reference to the 6 CDR domains shown in Figure 17 and further specifies the glycosylation site by reference to the sequence of CDR1 of the immunoglobulin heavy chain. Support for describing antibodies by reference to specific CDR regions is found in the specification at page 38, lines 19-22:

> Particularly, the glycan-modified antibodies are derived from the human monoclonal antibody Krix-1, fragments thereof or contains one or several complementary determining region thereof.

Support for the glycosylation site located in the CDR1 of the immunoglobulin heavy chain is found in the specification at page 38, lines 23-25:

> Particularly [the antibodies] are genetically modified antibodies containing the mutations Asn47Glu (Krix-1E) and Thr49Ala (Krix-1A) in the CDR1 of the heavy chain of Krix-1.

As stated above, support for the individual CDR sequences specified in new claim 64 is found in Figure 17, where the individual CDR sequences corresponding to SEQ ID NOS: 33-38 are underlined. An amended sequence listing incorporating SEQ ID NOS: 33-38 and an amended Figure 17 adding the appropriate sequence identification numbers (SEQ ID NOS: 33-38) are provided herewith.

New claim 65 refers to particular mutations in the glycosylation site of the immunoglobulin heavy chain. Support for this amendment is also found in the specification at page 9, lines 11-15, and page 12, lines 5-7.

No new matter has been added by the present amendment. Applicants reserve the right to pursue any canceled subject matter in this or a continuation application.

CONCLUSIONS

Transmitted herewith is payment of $208.00 for the fee under 37 C.F.R. 1.16(i) for 8 additional claims. If there are any additional charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 24 February 2009

James D. DeCamp
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045